Navigation Links
Widespread support for nonembryonic stem cell research, VCU Life Sciences Survey shows
Date:12/18/2007

The VCU Life Sciences Survey is the first poll to reflect the discovery reported internationally in November that human skin cells can be used to create stem cells or their near equivalents. When asked about the implications of this development, more than six in 10, or 63 percent, say that both embryonic and non-embryonic stem cell research is still needed, 22 percent say this development means embryonic stem cell research is no longer necessary. Thirty-eight percent of Americans report hearing about this research.

Three-quarters of the U.S. public supports stem cell research that does not involve human embryos. Majorities of nearly all groups in society, including those with differing beliefs about abortion and religious commitment, favor non-embryonic stem cell research, according to the survey released Wednesday.

The findings are part of this years nationwide survey conducted by VCU via telephone with 1,000 adults nationwide from Nov. 26, 2007, to Dec. 9, 2007. The polls margin of error is plus or minus 3 percentage points. The survey is conducted for VCU Life Sciences and the VCU College of Humanities and Sciences by the VCU Center for Public Policy.

Other survey findings:

  • Embryonic stem cell research. A majority (54 percent) of Americans strongly or somewhat favors embryonic stem cell research, a figure that has remained about the same since 2004. As in past surveys, opinion on embryonic stem cell research is strongly related to views on abortion, religious commitment and self-assessed knowledge about stem cell research. The partisan divide over embryonic stem cell research remains roughly the same since 2004.

  • Personal impact of genetic research. Roughly four in 10, or 38 percent, report having a disease or medical condition strongly related to genetic factors or having a family member with such a disease or condition. Among this group, 57 percent say that medical research on genes and genetics has a positive affect on their life, 38 percent say this research hasnt affected their lives and 3 percent say it has a negative affect.

  • Cloning and therapeutic cloning. Opinion about therapeutic cloning is evenly divided with 47 percent in favor and 47 percent opposed to using cloning technology for the development of new medical treatments. When cloning is not restricted to therapeutic purposes, about eight in 10, or 81 percent, oppose the use of cloning technology in humans. Opinion on both issues has been fairly stable since the first VCU Life Sciences Survey was conducted in 2001.

  • Animal research. Medical research has long involved testing on animals. About six in 10, or 62 percent of adults, favor the use of animals in medical research either strongly or somewhat, while 35 percent are opposed.

  • Morality and ethics in scientific decisions. A majority, 51 percent, of the public says that scientific decisions should be based primarily on an analysis of the risks and benefits involved rather than the moral and ethical issues involved (32 percent). At the same time, a majority, or 63 percent, agrees that scientific research doesnt pay enough attention to the moral values of society.

  • Whats the governments role" Opinion about the governments role in regulating scientific research is mixed. A 46 percent plurality says that government regulation is necessary to protect the public interest, while 39 percent say government regulation does more harm than good. At the same time, 57 percent of Americans disagree with the idea that government rules will keep us safe from any risks linked to modern genetic science.


'/>"/>

Contact: Anne Buckley
albuckley@vcu.edu
804-828-6052
Virginia Commonwealth University
Source:Eurekalert

Related biology news :

1. New research to help fight widespread potato disease
2. M2SYS Partners with SecuGen Corporation to Support Market Leading Hamster Plus Fingerprint Reader with Auto-On Technology
3. Diet support helps chronic kidney patients
4. Entrust Continues Leadership by Adding Support for Next-generation E-Passports
5. $10 million gift to support cutting-edge epigenome center at USC
6. Grant supports study of abnormal ring-shaped chromosomes
7. Fossil record supports evidence of impending mass extinction
8. An intelligent new way to support the teaching of evolution
9. Gene study supports single main migration across Bering Strait
10. IdentiPHI Opens Paris Office to Boost European Sales and Support
11. Breakthrough technology observes synapse in real time, supporting theory of vesicular recycling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 2017  Genos, a community for personal genetic ... received Laboratory Accreditation from the College of American ... laboratories that meet stringent requirements around quality, accuracy ... "Genos is committed to maintaining the ... honored to be receiving CAP accreditation," said ...
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... Feb. 16, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage ... find a better treatment for triple negative breast cancer (TNBC), ... France program. The YEi Start ... designed to help entrepreneurs grow their business in ... eight American companies selected to complete an intensive one week ...
(Date:2/16/2017)... , Feb. 16, 2017  ArmaGen, Inc., a ... therapies to treat severe neurological disorders, today reported ... with AGT-181, the company,s investigational therapy for the ... as mucopolysaccharidosis type I, or MPS I). The ... (POC) study, presented today at the 13 th ...
(Date:2/16/2017)... Feb. 16, 2017   Biostage, Inc. (Nasdaq: ... biotechnology company developing bioengineered organ implants to treat cancers ... trachea, announced today the closing on February 15, 2017 ... of common stock and warrants to purchase 20,000,000 shares ... million. The offering was priced at $0.40 per share ...
(Date:2/16/2017)... , Feb. 16, 2017  Dermata Therapeutics, LLC, ... to treat a variety of dermatological diseases, today ... 1a financing and entered into a $5 million ... intends to use the capital for general corporate ... advancements in the treatment of serious diseases treated ...
Breaking Biology Technology: